Molecular diagnosis in chronic myeloid leukemia and mutation detection in Imatinib resistant patients
博士 === 慈濟大學 === 醫學研究所 === 98 === The BCR-ABL fusion protein is a constitutively activated tyrosine kinase that plays a central role in the pathogenesis of chronic myeloid leukemia (CML) and Philadelphia (Ph) chromosome-positive acute lymphoid leukemia (ALL). The aberrant tyrosine kinase activity of...
Main Authors: | JU-HUEI CHIEN, 簡如慧 |
---|---|
Other Authors: | Chan-Ping Lee |
Format: | Others |
Language: | en_US |
Published: |
2010
|
Online Access: | http://ndltd.ncl.edu.tw/handle/11499581818752295819 |
Similar Items
-
Detection of BCR-ABL T315i mutation in imatinib resistant chronic myeloid leukemia patients
by: Mardziah M, et al.
Published: (2019) -
Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01) -
Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01) -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
by: Tomasz Sacha
Published: (2013-12-01) -
Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase
by: Ol'ga Yur'evna Vinogradova, et al.
Published: (2009-07-01)